Göhler et al. Final 21.06.2023

1	Comparative Analysis of Nebulizers in Clinical use for
2	Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)
3	
4	Short title: Technical characterisation of PIPAC nebulizers
5	
6	Daniel Göhler, DiplIng. ^{1,2} , Kathrin Oelschlägel, DiplIng ¹ , Mehdi Ouaissi, Prof, MD,
7	PhD ^{3,4} , Urs Giger-Pabst, Prof, MD ^{3,5}
8	
9	¹ Topas GmbH, Dresden, Germany
10	² Research Group Mechanical Process Engineering, Institute of Process Engineering and
11	Environmental Technology, Technische Universität Dresden, Dresden, Germany
12	³ EA4245 Transplantation, Immunology, Inflammation, Université de Tours, France
13	⁴ Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver
14	Transplant Surgery, University Hospital of Tours, France
15	⁵ Fliedner Fachhochschule, University of Applied Science Düsseldorf, Düsseldorf, Germany
16	
17	
18	Corresponding author:
19	Urs Giger-Pabst, MD
20	University of Applied Science
21	Fliedner Fachhochschule
22	Geschwister-Aufricht-Straße 9
23	40489 Düsseldorf, Germany
24	E-Mail: ursgiger@gmx.net
25	Phone: +49 163 729 44 07
26	
27	
28	Key words
29	Pressurized Intraperitoneal Aerosol Chemotherapy, PIPAC, aerosol droplet size, gravimetry,
30	Nebulizer, MCR-4 Topol [®] , HurriChem TM , QuattroJet NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1

Göhler et al. Final 21.06.2023

32 Author Contributions

Daniel Göhler and Urs Giger-Pabst: study design, experiments, data acquisition, data
interpretation and drafting of manuscript.

- 35 Kathrin Oelschlägel and Mehdi Ouaissi: critical revision for important intellectual content of
- the manuscript according to their field of research.

37 **Disclosure**

38 Strictly academic study supported by institutional funds. All authors have no conflicts of 39 interest or financial ties to declare.

40 Data Availability Statement

All relevant data are within the manuscript. Raw data will be provided by the correspondingauthor upon request.

43 Legal background

44 Purely technical analyses without the use of biological material or patients requiring no specific
45 legal authorization or ethics vote.

46 Acknowledgments

The authors thank Professor Marc Pocard, Hepato-Biliary-Pancreatic Gastrointestinal Surgery
and Liver Transplantation, Pitié Salpêtrière Hospital, AP-HP, F-75013 Paris, France, for
providing a HurriChem[™] (ThermaSolutions, White Bear Lake, MN, USA) nozzle.

Göhler et al. Final 21.06.2023

51 Abstract

Objective: Technical ex-vivo comparison of commercial nebulizer nozzles used for Pressurized
 Intraperitoneal Aerosol Chemotherapy (PIPAC).

Methods: The performance of four different commercial nebulizer nozzles (Nebulizer; HurriChemTM; MCR-4 TOPOL[®]; QuattroJet) was analysed by comparing: i) technical design and principle of operation, ii) operational pressure as function of the liquid flow rate, iii) droplet size distribution via laser diffraction spectrometry, iv) spray cone angle, spray cone form, and horizontal drug deposition through image-metric analyses, and v) chemical resistance via exposing to a cytostatic solution and metallurgic composition by means of spark optical emission spectral analysis.

Results: The Nebulizer exhibits a nearly identical technical design, implying a comparable 61 performance (e.g., mass median droplet size of 29 µm) as the original PIPAC nozzles (MIP/ 62 CapnoPen). The other three nozzles demonstrate varying degrees of performance deviation 63 from the original PIPAC nozzles. The HurriChemTM shares a similar design and principle of 64 operation as the Nebulizer, but produces a finer aerosol with a particle size of 22 µm. The 65 operating principles of MCR-4 TOPOL[®] and QuattroJet significantly differ from that of the 66 original PIPAC nozzle technology. The MCR-4 TOPOL® nebulizer has a hollow spray cone 67 that leads to the production of significantly larger aerosol droplets (50 µm) compared to the 68 69 original PIPAC nozzles. The QuattroJet generates an aerosol droplet (22 µm) similar in size to the HurriChemTM and exhibits improved spatial drug distribution. 70

Conclusion: While the introduction of new PIPAC nozzles is a welcome development,
differences in performance and efficacy were noted. Therefore, it is recommended that PIPAC
nozzles that deviate from the current standard undergo bioequivalence testing and be
implemented in accordance with the IDEAL-D framework prior to routine clinical use.

Göhler et al. Final 21.06.2023

76 **1** Introduction

More than a decade ago, Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) was 77 78 introduced clinically as a new approach to deliver intraperitoneal chemotherapy to patients suffering from end-stage peritoneal surface malignancies. Using a high-pressure injector 79 80 connected to a specially designed PIPAC nozzle, liquid chemotherapeutic drugs are aerosolised during laparoscopic surgery within the capnoperitoneum. This approach is expected to have a 81 82 better spatial drug distribution pattern, greater depth of tissue penetration, and higher drug concentration in the tissue than conventional liquid intraperitoneal chemotherapy [1, 2]. 83 84 Clinical data from phase I/II and larger mono- and multicentre case series regarding safety, feasibility, and oncologic efficacy are encouraging. While the therapeutic role of PIPAC 85 remains uncertain [3], there are ongoing prospective randomized PIPAC trials, and their results 86 are eagerly awaited [4, 5]. 87

Until recently, the original PIPAC nozzle was the only option available for clinical use. More 88 than 18`000 documented clinical applications worldwide were recorded by the end of 2022 [3]. 89 Significant efforts have been dedicated to standardizing PIPAC therapy globally in order to 90 compare efficacy. [6, 7]. Technical and clinical performance of the original PIPAC nozzle have 91 been extensively studied in pre- and clinical settings [3, 8, 9]. The recent introduction of new 92 93 nebulizer devices and their clinical use requires a detailed evaluation of their physical properties. As of now, very limited comparative data are available for the newly introduced 94 95 PIPAC nozzles. Oncological surgeons are now confronted with the question of whether these newer nozzles are equivalent to the original nozzle technology or if they possess potential 96 97 technical or functional advantages or disadvantages that could impact oncological outcomes.

Building upon the methodological findings regarding the technical characterization of the
original PIPAC nozzle [8], the present study focuses on the comparative performance
characterization of four commercially available nebulizers commonly used in PIPAC
procedures.

- 102
- 103
- 104
- 105

Göhler et al. Final 21.06.2023

106 2 Materials and Methods

107 2.1 Examined PIPAC nozzles

Four commercial single-substance PIPAC nozzles for intraperitoneal drug aerosolization wereexamined, i.e.,

• Nebulizer, Model 770-12, REGER Medizintechnik, Villingendorf, Germany (A),

• HurriChemTM, ThermaSolutions, White Bear Lake, MN, United States of America (B),

• MCR-4 TOPOL[®], SKALA-Medica, Sobĕslav, Czech Republic (C),

• QuattroJet, Model 770-14, REGER Medizintechnik, Villingendorf, Germany (D).

After the experiments, all nozzles were longitudinally cut open in the middle at a 180° angle using a computerized numerical control milling machine to investigate their principles of operation. In addition, also the dimensions of the nozzle outlet orifices were examined by light microscopy (SMZ1500, Nikon, Tokyo, Japan).

118 2.2 Barometric characterisation of operational pressure as function of liquid flow rate

To characterise the operational pressure over the volumetric liquid flow rate, the nozzles were 119 connected via high-pressure hose lines with a high-pressure injector (ACCUTRON[®] HP-D, 120 MEDTRON AG, Saarbrücken, Germany) to push the test liquid (Glucosterile 5%, Fresenius 121 Kabi GmbH, Germany) through the nozzles. The operational pressure induced by the liquid 122 flow rate was determined by means of a glycerine-filled bourdon gauge (MA7U-25, JRA 123 124 Maschinenteile und Geräte GmbH, Reichenbach, Germany), which was implemented in the high-pressure line. For the analyses, the volumetric liquid flow rate was increased stepwise 125 either by 0.1 ml/s (for nozzles A, B and D) or by 0.2 ml/s (for nozzle C) until the maximum 126 permitted pressure of 21 bar of the high-pressure injector was reached. For nozzle D, only the 127 axial nozzle was tested - the horizontal nozzles were sealed watertight. Analogous to [8], 128 measurement values were taken at steady state conditions of the aerosolization process, and all 129 analyses were repeated three times. 130

131 2.3 Granulometric characterisation of droplet size distributions

The droplet size distributions of the aerosols generated from the test liquid (Glucosterile 5%,
Fresenius Kabi GmbH, Germany) were characterised by laser diffraction spectrometry
(PW180-C spray particle size analyser, Jinan K-Ring Technology Co., Ltd, Shandong, China)

Göhler et al. Final 21.06.2023

over a size range of (0.57 - 780) µm. The outlets of the PIPAC nozzles were arranged via a
tripod in a distance of 5 mm perpendicular to the centre of the free-accessible red laser beam.
To characterise the aerosolization performance, all analyses were performed contemporaneous
with the barometric characterisation of the operational pressure for various liquid flow rates.
Analogous to [8], measurement values were taken at steady state conditions of the
aerosolization process and all analyses were repeated three times.

141 2.4 Image-metric characterisation of spray cone angles, form and horizontal drug 142 deposition areas

- The spray cone angles, the form of the spray cones and the horizontal drug deposition area were characterised with different test liquids at nozzle-specific operation conditions as recommended by the manufacturers, i.e., at a volumetric liquid flow rate of 0.5 ml/s for the nozzles A, B, at 2.0 ml/s for nozzle C and 1.5 ml/s for nozzle D. The former two characteristics were evaluated on the base of a 5 wt.-% aqueous glucose solution (Glucosterile 5%, Fresenius Kabi GmbH, Germany), while the latter characteristic was assessed by operating the nozzles with undiluted royal blue ink (Pelikan Tinte 4001[®], Hannover, Germany).
- For the spray cone angle analyses, the nozzles were fixed on a tripod and vertically aligned.
 Photographic images were taken with a camera that was perpendicular positioned to the nozzle direction. The images were in-silico processed by overlaying with a digital 360° full-circle protractor for determining the spray cone angles.
- The form of the spray cones was visualized by means of a line laser (GCL 2-15, Robert Bosch Power Tools GmbH, Leinfelden-Echterdingen, Germany) positioned in distance of 60 mm from the nozzle orifice at right angle into the spray cone. Fully evaluated spray cone forms were finally documented photographically.
- The horizontal drug deposition on a level-aligned blotting paper was examined by operating the vertically aligned nozzles with a distance of 60 mm between the blotting paper and the nozzle orifice. The blotting paper was exposed for 3 s to the fully-developed spray jet. To achieve this, a mechanical diaphragm was placed in front of the spray jet. The diaphragm was opened automatically within 0.1 s, when the aerosol jet showed steady state nebulisation condition.
- 163
- 164

Göhler et al. Final 21.06.2023

165 2.5 Assessing of chemical resistance and chemical composition

To assess the chemical resistance of the nozzle material against chemotherapeutic drugs, the 166 nozzles were at first exposed to a cytostatic solution for 12 hours and afterwards stored in the 167 dark at room temperature for 12 days within petri dishes. The chosen cytostatic solution was 168 prepared in accordance to the mixture of high pressure/high dose PIPAC (HP/HD-PIPAC) [10], 169 i.e., 6 mg of doxorubicin (Accord 2 mg/ml, Accord Healthcare GmbH, Munich, Germany) was 170 admixed to a total volume of 50 ml with a 0.9 wt.-% aqueous sodium chloride solution (Ecolav® 171 100, B. Braun, Melsungen, Germany). Finally, the nozzles were milled open in a laminar flow 172 workbench and macroscopic changes were documented photographically. 173 Furthermore, the chemical composition of the nozzles pipes was characterised for the following 174 175 elements: C, Si, Mn, P, S, Cr, Ni, Mo, Cu, W and N by means of spark optical emission spectral analysis (SPECTROMAXx, SPECTRO Analytical Instruments GmbH, Kleve, Germany) via 176 an independent, state-recognized laboratory (WS Material Service GmbH, Essen, Germany). 177

178

179 **3 Results**

180 3.1 Technical design and principle of operation

181 The 90° sectional views of the head regions in Figure 1 show technical destails of the examined182 nozzles.

Göhler et al. Final 21.06.2023




Figure 1: 90° sectional views of the head regions of the nozzles. Legend: O = outlet orifice; H = nozzle
head; I = bar inlay with distal transverse borehole; M = double metal grid; N = fixed needle; S = shaft;
T = twist body.

Externally, all nozzles consist of a stainless steel shaft (S) with a more or less pronounced nozzle head (H) on the lower part and a Luer lock thread on the upper part (not shown in Figure 1). The Luer lock threads serve for the connection of the nozzles with high-pressure injectors via high-pressure hose lines. Internally, the nozzles show considerable differences (Figure 1). It is worth noting that nozzle A and B exhibit a nearly identical construction and principle of operation. However, both nozzle C and D differ significantly from each other and from nozzle A and B

In the case of the nozzles A, B and D, the liquid drug is supplied internally from the Luer lock connector to the nozzle head via an annular gap between the outer shaft (S) and a bar inlay with distal transverse borehole (I). In contrast, the internal liquid drug supply of nozzle C occurs directly via the hollow cavity of the shaft (S). Moreover, nozzle C is equipped with a double metal grid (M) with two different mesh sizes that serve as particle filter.

While the nozzles A and B contain one twist body (T), nozzle D is equipped with four twist bodies (i.e., with one axial and three lateral twist bodies in 120° arrangement) to improve the spatial drug distribution within the abdominal cavity. The twist bodies (T) of the nozzles A, B

Göhler et al. Final 21.06.2023

and D contain longitudinally superfically milled grooves at 180° intervals. As the liquid drug flow rate passes along the twist bodies (T) they were set into rotation that improves the aerosolisation prior leaving the nozzle via the outlet orifice (O). In the case of nozzle C, the twist body is replaced by an fixed metal needle (N). This needle contains also laterally located, spirally milled axial grooves that induce a whirlwind effect for aerosolisation when passed by the liquid flow before leaving the nozzle via the outlet orifice (O).

Light microscopic images of the oulet orifices (O) with determined orifice diameters of the examined nozzles are shown in Figure 2.





Figure 2: Light microscopic images of the outlet orifices with determined orifice diameters of the
examined nozzles; scaling in mm. Nozzles A, B, C, D

213 3.2 Operational parameters based on barometric and granulometric analyses

In Figure 3a, the operational pressure of the examined nozzles is shown as a function of the 214 liquid flow rate. Figure 3b displays the mass median diameter of the droplet size distribution 215 over the operational pressure. To avoid artefacts due clouding of the optics of the laser 216 217 diffraction spectrometer, the lateral nozzles of nozzle D (QuattroJet) were taped off for the granulometric analyses and a flow rate of 0.5 ml/s was chosen (manufacturer-recommended 218 219 flow rate of 1.5 ml/s) Note that the shown data are determined at steady state conditions of the aerosolization process analogous to [8]. Figure 3a shows that the determined operational 220 pressure data for all examined nozzles fit well with the fluid dynamic theory, i.e., the dynamic 221 pressure (or the dynamic pressure drop) of an incompressible fluid increases with the fluid 222 223 velocity by the power of two. According to the equation of continuity, the fluid velocity of an incompressible fluid is in turn directly proportional to the volumetric liquid flow rate. The 224 nozzles A, B and D show a similar performance regarding operational pressure and liquid flow 225 rate, while nozzle C (MCR-4 TOPOL[®]) has a significantly lower pressure drop, and thus, a 226 considerable higher volumetric liquid flow rate at a specific operational pressure. 227

Göhler et al. Final 21.06.2023

228 In addition to the entire operational spectrum, the study also separately investigated the manufacturer-recommended operational conditions, i.e., at a volumetric liquid flow rate of 229 0.5 ml/s for nozzle A (Nebulizer) and nozzle B (HurriChemTM), 1.3 - 2.0 ml/s for nozzle C 230 (MCR-4 TOPOL®) and 1.5 ml/s for nozzle D (QuattroJet). Under these conditions nozzle C 231 showed with (18 - 26) s the shortest initiation time to reach the corresponding steady state 232 pressure of (7.4 - 18.1) bar, followed by nozzle A with 52 s (15.7 bar) and nozzle D with 94 s 233 (16.0 bar). Note that with taped-off lateral nozzles, nozzle D shows a higher operational 234 pressure of 19.3 bar (as shown in Figure 3). 235



236

Figure 3: Operational pressure as function of the liquid flow rate from barometric analyses (a), massmedian diameter as function of the operational pressure from granulometric analyses (b) and volume-

Göhler et al. Final 21.06.2023

weighted distributions density (c) and cumulative distribution (d) of droplets at certain manufacturer recommended operational condition; black cycles/ellipses indicate manufacturer-recommended
 operation condition.

242 Figure 3b shows that the mass median diameter of the generated droplet aerosols depends for each nozzle significantly on the operational pressure. With increasing operational pressure, the 243 244 mass median diameter decreases. For operational pressures of ≤ 4 bar, no significant differences between the different nozzles were observed. This is attributed to a non-fully developed 245 246 aerosolization of the supplied liquid. For operation pressures of ≥ 5 bar stable aerosol generation is reached and differences between the nozzles can be observed. For operational pressures ≥ 5 247 bar, nozzle C (MCR-4 TOPOL[®]) shows the coarsest mass median diameters, followed by 248 nozzle A (Nebulizer). The finest mass median diameters were determined for nozzle B 249 250 (HurriChemTM) and D (QuattroJet).

The same ranking can also be deduced by the volume-weighted droplet size distributions of the aerosols as generated by the nozzles at the manufacturer-recommended operation conditions (Figure 3c, Figure 3d). Moreover, it can be observed in Figure 3c and Figure 3d, that each aerosol has a polydisperse and bimodal droplet size distribution.

255 3.3 Operational parameters based on image-metric analyses

Figure 4 shows photographic images for the spray cone angle (upper panel), the spray cone form (mid panel) and the horizontal drug deposition area (lower panel) of each examined nozzle

as determined at manufacturer-recommended operational conditions.

Göhler et al. Final 21.06.2023




Figure 4: Photographic images of spray cone angle (upper panel), of spray cone form (middle panel)and horizontal drug deposition area (lower panel, scale in cm). Nozzles A, B, C, D.

According to the upper panels of Figure 4, the widest single spray cone angle, 79°, was achieved 262 with nozzle C (MCR-4 TOPOL[®]), 72° for nozzle A (Nebulizer), 71° for nozzle B 263 (HurriChemTM), and 67° for nozzle D (QuattroJet). While Nozzle D exhibits the smallest single 264 spray cone angle (67°) , it should be noted that unlike the other nozzles, Nozzle D consists of 265 four spray cones. As shown in the middle panels of Figure 4, nozzle A (Nebulizer), nozzle B 266 (HurriChemTM) and nozzle D (QuattroJet) generate a full spray cone, whereas nozzle C (MCR-267 4 TOPOL[®]) produces a hollow spray cone. The full spray cones of the nozzles A, B and C lead 268 to completely filled circular areas of horizontal drug deposition beneath the nozzles as shown 269 in the lower panel of Figure 4. In the case of the nozzles A and B, a circular deposition area of 270 271 approx. 38.5 cm² (outer diameter of approx. 7 cm) was determined. The lateral outlets of nozzle D showed in addition to the axial circle (outer diameter of approx. 7 cm) 3 additional deposition 272

Göhler et al. Final 21.06.2023

- areas of (13×20) cm that accumulate to an overall horizontal deposition area of approx.
- 274 679 cm².

275 3.5 Chemical resistance and chemical composition

- 276 Photographic images of the nozzle parts after prolonged exposure to the cytostatic solution are
- shown in Figure 5.



278

Figure 5: Photographic images of the nozzle parts after exposure to the cytostatic solution. Nozzle A,
B, C, D.

As shown in Figure 5, no macroscopic corrosion was observed except for nozzle C (MCR-4 TOPOL[®]). Prolonged exposure to cytostatic solution led to the formation of iron oxide. Corrosion was particularly pronounced on the fine-mesh particle filter, the nozzle needle, and the nozzle head housing. No changes were observed for the nozzles A, B and D either visually or by light microscopic analyses.

Analysis of chemical composition revealed that nozzles A, B and D fulfil requirements of stainless steel 1.4301, typically used for surgical instruments according to EN 10088-3:2014 [11]. Nozzle C (MCR-4 TOPOL[®]) showed a twelve times higher quantity of sulphur (0.012 wt.-% vs. 0.001wt.-%). In addition, molybdenum (0.183 wt.-%), copper (0.220 wt.-%) and tungsten (0.134wt.-%) were identified by spark optical emission spectrometry for nozzle C.

292

293 **4 Discussion**

Given the current lack of knowledge, this study conducted a comparative performance analysis
of four clinically used nebulizing nozzles for PIPAC. The key technical characteristics of these
nozzles are summarised in Table 1.

Göhler et al. Final 21.06.2023

Table 1: Overview on technical and functional characteristics of the examined nozzles; * =
 manufacturer-recommended operational conditions.

parameter	unit	A (Nebulizer)	B (HurriChem TM)	C (MCR-4 TOPOL®)	D (QuattroJet)
*liquid flow rate (*QL)	ml/s	0.5	0.5	1.3 - 2.0	1.5
operational pressure for *QL	bar	15.7	14.9	7.4 - 18.1	16.0
pressure initiation time for $*Q_L$	s	52	100	18 - 26	94
nozzle orifice diameter	μm	200	190	370	170
mass median diameter for 15 bar	μm	28.95	20.99	52.17	24.18
max. spray angle for $*Q_L$	0	≈ 72	≈ 71	≈ 79	≈ 67
number of nozzles	-	$1 \times axial$	$1 \times axial$	1 imesaxial	$1 \times axial, 3 \times lateral$
kind of spray cone	-	full cone	full cone	hollow cone	full cone
drug deposition area for *QL	cm ²	≈ 38.5	≈ 38.5	≈ 66	≈ 679

299

Nozzle A (Nebulizer) shows after an initiation time of 52 s an operational pressure of 15.7 bar at the manufacturer-recommended operational liquid flow rate of 0.5 ml/s. Thereby, a full spray jet cone (71°) composed of droplets with a mass median diameter of 29 μ m is formed. The data of this study reveal that nozzle A is identical in design and performance to the nozzle type that was already introduced 10 years ago for clinical use (microinjection pump (MIP)) [8], which was also distributed under the tradename CapnoPen.

Nozzle B (HurriChemTM) is another nebulizer that has recently been introduced for PIPAC use. Examinations on design and principle of operation show a high similarity with nozzle A (Nebulizer) and thus also with the initial PIPAC nozzle technology. At the manufacturerrecommended operational liquid flow rate of 0.5 ml/s, nozzle B shows after an initiation time of 100 s an operational pressure of 14.9 bar. The mass median diameter of the droplets in the formed full spray jet cone (73°) was determined to be 21 µm.

Nozzle C (MCR-4 TOPOL[®]) differs from other nozzles investigated in terms of technical design, principle of operation, operational parameters, and aerosol characteristics. The operation of nozzle C is accompanied by the formation of a hollow spray cone jet (79°). At the manufacturer-recommended operational liquid flow rate range of (1.3 - 2.0) ml/s, operational pressures of (7.4 - 18.1) bar were reached rapidly (18 - 26) s. The mass median droplet size decreases with increasing liquid flow rate but was found to be in each case larger than 50 μ m.

Nozzle D (QuattroJet) is a further PIPAC nebulizing nozzle that was introduced by the same
manufacturer as for nozzle A. To optimize the spatial drug distribution pattern and achieve

Göhler et al. Final 21.06.2023

higher intraabdominal aerosol particle concentration, the conventional axial nozzle is supplemented in nozzle D by three further nozzles, which are arranged lateral at the nozzle head with an angular distance of 120°. Nozzle D is based on the same technology as nozzle A. At the manufacturer-recommended flow rate of 1.5 ml/s, nozzle D shows an operational pressure of 16.0 bar after an initiation time of 92 s and provides four full spray cone jets (67°) composed of droplets with a mass median diameter of 21 μ m.

Recently, a first attempt regarding recommendations on the minimum technical requirements 326 on nozzles suitable for PIPAC treatment was published. A minimum requirement for the spray 327 angle of at least 70° was defined [12] by implying that the spray cone angle corresponds to the 328 achievable drug deposition area. In this study we found that not all nozzles fulfil this 329 requirement. The requirement is matched by nozzles A, B and C. Nozzle D achieves a slightly 330 lower spray cone angle (67°) than required, however the four spatially-displaced spray jets 331 achieve a total spray angle of 268°. Nozzle C, unlike all other nozzles examined, produces a 332 333 hollow spray cone, resulting in a ring-shaped drug deposition area that was smaller than that of a full spray cone jet at the same spray cone angle. Regarding nozzle performance, the drug 334 deposition area seems to be an even better technical parameter than the spray cone angle. 335

The nozzles C (MCR-4 TOPOL®) and D (QuattroJet) investigated in this study, in contrast to 336 A (Nebuliser) and B (HurriChemTM), and thus in contrast to the primary PIPAC nozzle 337 technology, show significant differences in their operating principle and performance. Nozzle 338 C offers the largest spray cone angle of all examined nozzles, but produces a hollow spray cone. 339 It is not known if such a spray jet improves drug distribution and drug penetration, since no 340 preclinical studies exist comparing a hollow with a full spray cone. Nozzle D provides multiple 341 spray cones that can significantly improve the spatial drug distribution by reduction of high 342 local deposition and thus high local tissue toxicity. Nonetheless, these potential benefits of 343 344 multi-nozzle systems need to be confirmed by further research.

In contrast to the other nozzles, nozzle C (MCR-4 TOPOL®) exhibits a macroscopically visible formation of iron oxide after long-term exposure to a cytostatic solution containing sodium chloride. Based on spark optical emission spectrometry, it was discovered that nozzle C was made from steel with a significantly higher sulphur content (0.012 wt.-% vs. 0.001 wt.-%), along with contamination of molybdenum (0.183 wt.-%), copper (0.220 wt.-%), and tungsten (0.134 wt.-%). Short-term exposure of the nebulizers to cytostatic solution reveals no

Göhler et al. Final 21.06.2023

immediate macroscopic corrosion. Nevertheless, it is not possible to completely rule out apotential risk to the patient.

Currently, there are only limited preclinical data to suggest that there is an optimal technique 353 for the generation and delivery of PIPAC aerosols that could improve clinical outcome. 354 However, it is clear that, contrary to claims made by one manufacturer [13], larger aerosol 355 droplets injected into the peritoneal cavity at higher velocities with a hollow spray cone do 356 neither improve the spatial distribution pattern [8, 14] nor tissue penetration depth per se. 357 Nebulizers differing from the present standard technology in design, especially in spraying 358 characteristics, cannot automatically be considered equivalent by the clinical user. Therefore, 359 before their broad clinical use, the individual innovation phases should be systematically tested, 360 ideally following the recommendation of the IDEAL-D framework for the introduction of 361 medical devices [15, 16]. While the original nozzle technology has completed phase I - IIb [17] 362 and phase III trials are ongoing [4, 5], only limited phase I clinical user data has been published 363 for nozzle C (MCR-4 Topol[®]) [18] and such data are lacking for nozzle B and D. 364

In the near future, clinical users should have the assurance that technical testing and reporting 365 adhere to scientific standards and widely accepted global standards, including ISO standards. 366 For PIPAC nebulizers, such standards should ideally be set by a panel of experts. Moreover, 367 nebulizers with significant technical and granulometric differences from the standard 368 technology should undergo first ex- and in-vivo animal testing before clinical use. 369 370 Manufacturers should be obliged to have the bioequivalence of the cytostatic drugs administered independently certified in comparison to standard nebulizer systems, analogous 371 372 to drugs and their generics. Relevant outcome measures are aerosol characteristics, spatial drug distribution, depth of penetration, tissue concentration and the peak concentration and the area 373 under the curve describing the extent of peritoneal passage [8, 19 - 28]. The ratio between the 374 individual properties of the generic nebulizer and the reference product would ideally be 1:1 in 375 376 case of bioequivalence. As this is unlikely to be achieved, the US Food and Drug Administration (FDA), for example, requires the 90% confidence interval for drugs and their 377 generics to be between 0.80 and 1.25 [29]. Similar to such FDA specifications, new PIPAC 378 nozzle technologies could be tested comparatively in the future. Such preclinical testing, ideally 379 using standardized models, could prevent the use of devices compromising clinical outcomes 380 and/or harming healthcare professionals/patients. Finally, it would be helpful for the 381

Göhler et al. Final 21.06.2023

comparability of clinical results if the nebulizer type used in each case will be also recorded in
 the PIPAC database (https://isspp.org/professionals/pipac-database/).

384

385 **5** Conclusion

Four clinically-used nozzles to aerosolise chemotherapeutic drugs in the context of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC), i.e., the Nebulizer, the HurriChemTM, the MCR-4 TOPOL[®] and the QuattroJet were comparatively examined to determine their performance.

390 We confirmed that the Nebulizer exhibits a nearly identical technical design, and thus similar performance to the original PIPAC nozzles MIP/CapnoPen. The PIPAC nozzle HurriChemTM 391 is based on a similar technical design as the Nebulizer nozzle but provides a finer aerosol due 392 to a smaller nozzle orifice opening. Both, the MCR-4 TOPOL[®] and the QuattroJet deviate in 393 the principles of design and operations from the Nebulizer, and thus, the original PIPAC 394 technology. While the MCR-4 TOPOL® provides the coarsest aerosol of the four nozzles 395 examined, the QuattroJet delivers an aerosol similar to that of the HurriChemTM. In contrast to 396 the HurriChemTM, the OuattroJet comes with the feature of four spray cones (one axial, three 397 lateral) to improve the spatial drug distribution and a higher aerosol particle number 398 399 concentration.

The availability of new PIPAC nozzles with unique features is encouraging but can also negatively impact optimization and standardization of PIPAC protocols for the treatment of peritoneal carcinomatosis. It is therefore recommended that nozzles for which the technical/granulometric characteristics differ from the current standard technology must be subjected to preclinical proof of equivalence in terms of spatial drug distribution, tissue penetration and concentration before routine clinical use. New nebulizers should be investigated and introduced for clinical use in accordance with the IDEAL-D framework.

Göhler et al. Final 21.06.2023

408 **References**

- Solaß W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA Description of a novel approach for intraperitoneal drug delivery and the related device. Surg. Endosc.
 2012;26(7):1849–1855. Doi: 10.1007/s00464-012-2148-0.
- 412 2. Solaß W, Kerb R, Mürdter T, et al. Intraperitoneal chemotherapy of peritoneal
 413 carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence
 414 for efficacy. Ann. Surg. Oncol. 2014;21(2):553–559. Doi: 10.1245/s10434-013-3213-1.
- Alyami M, Hübner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy:
 rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368–e377. Doi:
 10.1016/S1470-2045(19)30318-3
- 4. Somashekhar SP, Ashwin KR, Rauthan A, Rohit KC Pressurized IntraPeritoneal Aerosol
 Chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases
 secondary to platinum resistant ovarian cancer study protocol for a randomized control
 trial. Pleura and Peritoneum 2019;4(1). Doi: 10.1515/pp-2018-0111
- 422 5. Casella F, Bencivenga M, Rosati R, et al. Pressurized intraperitoneal aerosol chemotherapy
 423 (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer:
 424 a randomized multicenter phase III trial PIPAC VEROne. Pleura and Peritoneum
 425 2022;7(3):135–141. Doi: 10.1515/pp-2022-0111
- 6. Sgarbura O, Villeneuve L, Alyami M, et al. Current practice of pressurized intraperitoneal
 aerosol chemotherapy (PIPAC): Still standardized or on the verge of diversification?
 European Journal of Surgical Oncology 2021;47(1):149–156. Doi:
 10.1016/j.ejso.2020.08.020
- 430 7. Sgarbura O, Eveno C, Alyami M, et al. Consensus statement for treatment protocols in
 431 pressurized intraperitoneal aerosol chemotherapy (PIPAC). Pleura and Peritoneum
 432 2022;7(1):1–7. Doi: 10.1515/pp-2022-0102
- Göhler D, Khosrawipour V, Khosrawipour T, et al. Technical description of the micro injection pump (MIP[®]) and granulometric characterization of the aerosol applied for Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Surg. Endosc.
 2017;31(4):1778–1784. Doi: 10.1007/s00464-016-5174-5
- 9. Nadiradze G, Horvath P, Sautkin Y, et al. Overcoming Drug Resistance by Taking
 Advantage of Physical Principles: Pressurized Intraperitoneal Aerosol Chemotherapy
 (PIPAC). Cancers 2020;12(1):34. Doi: 10.3390/cancers12010034.

Göhler et al. Final 21.06.2023

- 440 10. Arias GR, Sindayigaya R, Ouaissi M, et al. Safety and Feasibility of High-Pressure/High-
- 441 Dose Pressurized Intraperitoneal Aerosol Chemotherapy (HP/HD-PIPAC) for Primary and
- 442 Metastatic Peritoneal Surface Malignancies. Ann. Surg. Oncol. 2022. Doi: 10.1245/s10434443 022-12698-4.
- 11. EN 10088-3:2014. Stainless steels Part 3: Technical delivery conditions for semi-finished
 products, bars, rods, wire, sections and bright products of corrosion resisting steels for
 general purpose.
- 447 12. Pocard M, So JBY, Huchon C, et al. PIPAC nebulizer: How to test the new devices in the
 448 market, expert recommendations. Journal of Visceral Surgery 2022. Doi:
 449 10.1016/j.jviscsurg.2022.10.001.
- 450 13. PIPAC Pressurized Intraperitoneal Aerosol Chemotherapy; https://www.skala.cz/en/mcr451 4-topol-en/ (access: 5th March 2023 at 11:02 CET)
- 452 14. Hinds, William C. (1999). Aerosol technology: properties, behaviour, and measurement of
 453 airborne particles. New York: Wiley. ISBN 978-0-471-19410-1.
- 454 15. Sedrakyan A, Campbell B, Merino JG, Kuntz R, Hirst A, McCulloch P IDEAL-D: a rational
 455 framework for evaluating and regulating the use of medical devices. Br. Med. J. 2016;i2372.
 456 Doi: 10.1136/bmj.i2372.
- 457 16. Páez A, Rovers M, Hutchison K, Rogers W, Vasey B, McCulloch P Beyond the RCT: When
 458 are Randomized Trials Unnecessary for New Therapeutic Devices, and What Should We
 459 Do Instead? Ann. Surg. 2021;275(2):324–331. Doi: 10.1097/SLA.00000000005053.
- 460 17. Baggaley AE, Lafaurie GBRC, Tate SJ, et al. Pressurized intraperitoneal aerosol
 461 chemotherapy (PIPAC): updated systematic review using the IDEAL framework. Br. J.
 462 Surg. 2022;110(1):10–18. Doi: 10.1093/bjs/znac284.
- 18. Hoskovec D, Dytrych P, Vocka M, Krska Z, Skala R MCR-4 TOPOL[®] new device for
 PIPAC first clinical use. Eur. J. Surg. Oncol. 2022;48(2):e155. Doi:
 10.1016/j.ejso.2021.12.308.
- 19. Rahimi-Gorji M, Debbaut C, Ghorbaniasl G, Cosyns S, Willaert W, Ceelen W Optimization
 of Intraperitoneal Aerosolized Drug Delivery: A Computational Fluid Dynamics (CFD) and
 Experimental Study. Scientific Reports 2021;12(1). Doi: 10.1038/s41598-022-10369-8.
- 469 20. Göhler D, Geldner A, Gritzki R, et al. Development of a rat capnoperitoneum phantom
- 470 (RCP) to study drug aerosol deposition in the context of anticancer research on peritoneal
- 471 carcinomatosis. Sci. Rep. 2021;11:21843. Doi: 10.1038/s41598-021-01332-0.

Göhler et al. Final 21.06.2023

- 472 21. Göhler D, Große S, Bellendorf A, et al. Hyperthermic intracavitary nano-aerosol therapy
- 473 (HINAT) as improved approach for pressurised intraperitoneal aerosol chemotherapy
- 474 (PIPAC): Technical description, experimental validation and first proof of concept.
 475 Beilstein J. Nanotechnol. 2017;8:2729–2740. Doi: 10.3762/bjnano.8.272.
- 476 22. Buggisch JR, Göhler D, Sobilo J, et al. Development and technical validation of an
 477 ultrasound nebulizer to deliver intraperitoneal pressurized aerosols in a rat colon cancer
 478 peritoneal metastases model. BMC Cancer 2022;22(570). Doi: 10.1186/s12885-022-09668479 0.
- 23. Rezniczek GA, Buggisch J, Sobilo J, et al. Establishment of a mouse ovarian cancer and
 peritoneal metastasis model to study intraperitoneal chemotherapy. Cancers 2020;12(12).
 Doi: 10.3390/cancers12123818.
- 483 24. Höltzcke P, Sautkin I, Clere S, Castagna A, Königsrainer A, Pott PP, Reymond MA.
 484 Feasibility of pressurized intra peritoneal aerosol chemotherapy using an ultrasound aerosol
 485 generator (usPIPAC). Surg Endosc. 2022 Oct;36(10):7848-7858. doi: 10.1007/s00464-022486 09525-y. Epub 2022 Aug 29. PMID: 36038646; PMCID: PMC9485099.
- 25. Toussaint L, Sautkin Y, Illing B, Weinreich FJ, Nadiradze G, Königsrainer A, Wichmann
 D. Correction to: Comparison between microcatheter and nebulizer for generating
 Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Surg Endosc. 2021
 Aug;35(8):4901. doi: 10.1007/s00464-021-08577-w. Erratum for: Surg Endosc. 2021
 Apr;35(4):1636-1643. PMID: 34106308; PMCID: PMC8263410.
- 492 26. Mun J, Park SJ, Kim HS. Rotational intraperitoneal pressurized aerosol chemotherapy in a
 493 porcine model. Gland Surg. 2021 Mar;10(3):1271-1275. doi: 10.21037/gs-2019-ursoc-11.
 494 PMID: 33842275; PMCID: PMC8033043.
- 27. Mimouni, M., Richard, C., Adenot, P. et al. Pressurized intra-peritoneal aerosol
 chemotherapy (PIPAC): increased intraperitoneal pressure does not affect distribution
 patterns but leads to deeper penetration depth of doxorubicin in a sheep model. BMC Cancer
 21, 461 (2021). https://doi.org/10.1186/s12885-021-07955-w
- 28. Giger-Pabst, U., Bucur, P., Roger, S. et al. Comparison of Tissue and Blood Concentrations
 of Oxaliplatin Administrated by Different Modalities of Intraperitoneal Chemotherapy. Ann
 Surg Oncol 26, 4445–4451 (2019). https://doi.org/10.1245/s10434-019-07695-z
- So2 29. Andrade C Bioequivalence of Generic Drugs: A Simple Explanation for a US Food and
 Drug Administration Requirement. Journal of Clinical Psychiatry 2015;76(06):e742–e744.
- 504 Doi: 10.4088/JCP.15f10094.